Mirum Pharmaceuticals, Inc. MIRM

FDA approves Atebrioz (zilurgisertib), a once-daily oral ALK2 inhibitor, to reduce total new heterotopic ossification (HO) in adults and patients 12+ with fibrodysplasia ossificans progressiva (FOP). Recommended dose is 100 mg daily. Atebrioz will be available in October via Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month. The PROGRESS program continues to evaluate zilurgisertib in younger children (Cohorts 2: 6 to <12 years; Cohort 3: 2 to <12 years). In Cohort 1, Week 24 showed a mean HO volume reduction of 3.2 cm3 vs a 24.6 cm3 increase with placebo, with effects maintained through Week 48 in the open-label extension. A Rare Pediatric Disease Priority Review Voucher was awarded to Incyte. EU MAA under EMA review; enrollment complete for Cohort 2 and ongoing for Cohort 3. Regulatory approval creates a meaningful near-term commercial opportunity in a rare indication, signaling validation and potential growth for Mirum.

Mirum Pharmaceuticals and Incyte awaited an FDA decision on zilurgisertib for fibrodysplasia ossificans progressiva (FOP), with a Sept. 26 target date. Zilurgisertib, an ALK2 inhibitor, could add a new commercial product for Mirum, which licensed worldwide rights from Incyte for $16 million upfront plus contingent regulatory and sales milestones and a mid-to-high-single-digit royalty on future sales. Incyte would also gain milestone payments and royalties if approved. Ipsen's Sohonos and Regeneron's garetosmab are competitors in the same indication. In a mid-stage study, one patient on zilurgisertib formed a new extra bone growth (3.1%) vs five on placebo (16.7%), while the total size of new growths fell by more than 99% vs placebo. Leerink suggested the data could still support approval. Shares moved modestly after opening higher. Approval would unlock Mirum's royalties and milestone payments and add a new commercial product, materially affecting its revenue trajectory amid competition.

MIRM and INCY stocks draw attention ahead of September 26 FDA ruling that may affect recent gains. September 26 FDA ruling holds potential to substantially alter MIRM trajectory and investor sentiment.

Mirum Pharmaceuticals raised its 2026 sales outlook but reported wider losses, triggering a 6.4% stock decline. Mixed sales guidance and loss expansion create moderate shifts in financial outlook and investor positioning without redefining core trajectory.

Mirum Pharmaceuticals issues Q2 2026 earnings call transcript covering financial results, operational updates and forward outlook. Quarterly earnings transcript supplies standard financial metrics and guidance that can shift near-term sentiment without guaranteeing major strategic shifts.

FDA's unexpected Phase 3 request clouds Mirum Pharmaceuticals' near-term outlook, triggering a 15% stock crash. Unexpected FDA Phase 3 request triggers 15% stock crash, signaling major regulatory setback for Mirum.

Mirum Pharmaceuticals' Q2 earnings missed estimates while revenues beat forecasts. The company raised its 2026 guidance. Mixed Q2 results with earnings miss offset by revenue beat and raised 2026 outlook indicate moderate effects on future performance.

Mirum Pharmaceuticals reported second quarter 2026 financial results and issued a business update. Quarterly financial results and business updates directly shape investor views and near-term stock trajectory.

Mirum Pharmaceuticals Q2 earnings call covered financial results, operational updates and future outlook. Quarterly earnings details provide financial and strategic updates that moderately affect performance and sentiment.

Mirum Pharmaceuticals held its Q2 2026 earnings call covering financial results, operational updates and outlook. Quarterly earnings calls deliver financial results and guidance that moderately influence near-term stock sentiment and operations.

Priority FDA review of Mirum Pharmaceuticals' FOP drug Zilurgisertib could alter the bull case for the company. Priority FDA review of key pipeline drug Zilurgisertib may significantly alter Mirum's market trajectory.

Mirum Pharmaceuticals releases new FOP data highlighting potential expansion in rare disease treatments and positioning the company for growth. New FOP clinical data signals major expansion opportunity in rare diseases that can shift company trajectory.

Mirum Pharmaceuticals and Incyte report positive rare disease data. FDA begins NDA review. Positive rare disease data plus FDA NDA review launch signal major regulatory and commercial upside for Mirum.

Mirum Pharmaceuticals and Incyte report positive rare disease data as FDA begins NDA review for Mirum. Positive rare disease data plus FDA NDA review start signal major regulatory progress and approval potential for Mirum's lead asset.

Mirum Pharmaceuticals and Incyte report positive rare disease data; FDA begins NDA review for Mirum. Positive rare disease data plus FDA NDA review start mark major regulatory and clinical progress for Mirum's lead asset.

Mirum Pharmaceuticals and Incyte announced positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva. Positive pivotal Phase 2 data for zilurgisertib bolsters Mirum pipeline value and investor outlook in rare disease space.

Mirum Pharmaceuticals and Incyte announce pivotal late-breaking results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva accepted for presentation at ENDO 2026. Pivotal Zilurgisertib data presentation acceptance at ENDO 2026 marks major pipeline progress for Mirum in FOP.

Mirum Pharmaceuticals reported positive Phase 2b data for Volixibat in PSC at EASL Congress. Positive Phase 2b data advances Volixibat development and can materially lift Mirum valuation and pipeline prospects.

Mirum Pharmaceuticals announced new data from its rare liver disease programs presented at the EASL International Liver Congress 2026. New clinical data presentation at major congress moderately influences market perception and pipeline validation for Mirum.

Mirum Pharmaceuticals enters catalyst-rich period with advancing LIVMARLI sales and pipeline progress. Catalyst-rich stretch with rising sales and pipeline advances signals major shifts in growth trajectory.

Mirum Pharmaceuticals issues US$600 million zero-coupon convertible notes, potentially altering the investment case and future capital structure for MIRM. US$600 million convertible note issuance marks major financing move with dilution risk and strategic impact on Mirum's trajectory.

Mirum Pharmaceuticals advances rare disease treatments with expanding pipeline and commercial momentum supporting sustained growth. Highlighting Mirum as a rare-disease growth story moderately lifts investor sentiment and visibility without detailing major new catalysts.

Mirum Pharmaceuticals (MIRM) priced a $600 million convertible senior notes offering to refinance a portion of its 2029 convertible notes. Pricing $600 million in convertible notes to refinance existing debt significantly strengthens the balance sheet and provides capital for operations and growth.

Mirum Pharmaceuticals, Inc. (MIRM) announces proposed convertible senior notes offering. Convertible senior notes offering represents a major financing strategy to raise capital for operations and growth, potentially diluting equity but enhancing liquidity.

Mirum Pharmaceuticals (MIRM) stock jumped 16.9% after positive Phase 2b data showing volixibat reduced itch in primary sclerosing cholangitis (PSC) patients, despite a large Q1 net loss of $42.8 million, raising questions on whether the bull case remains intact. Positive Phase 2b volixibat data in PSC itch triggered a 16.9% stock surge, indicating significant pipeline advancement despite Q1 losses.

Mirum Pharmaceuticals' Q1 earnings and revenues beat estimates, leading to a raised 2026 outlook. Beating Q1 estimates and raising 2026 guidance signals strong growth momentum and positive investor sentiment.

Mirum Pharmaceuticals released Q1 earnings call highlights, covering revenue growth, pipeline advancements in rare liver diseases, regulatory updates, and reaffirmed full-year guidance amid strong commercial performance. Q1 earnings highlights detail financial results, pipeline progress, and guidance that significantly shape investor expectations and stock trajectory.

Mirum Pharmaceuticals, Inc. released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 2026 earnings summary discloses financial performance and strategic outlook, likely driving significant shifts in market valuation and investor confidence.

Mirum Pharmaceuticals (MIRM) Q1 2026 earnings call transcript covers quarterly financial results, product updates, pipeline progress, and forward-looking guidance. Quarterly earnings transcripts disclose key financials, revenue growth, and strategic updates that drive stock volatility and long-term investor sentiment.

Key metrics from Mirum Pharmaceuticals (MIRM) Q1 earnings reveal insights into revenue, profitability, and operational efficiency. Q1 earnings metrics influence financial performance and investor sentiment but face balance from future quarters.